BioRestorative Therapies Receives A Notice Of Allowance By The United States Patent And Trademark Office For A Patent Application Related To Its Obesity Program
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies, Inc. (BRTX) has received a notice of allowance from the USPTO for a patent application related to its ThermoStem program for obesity and metabolic disorders. This will be the fourth U.S. patent in this patent family, covering methods using human brown fat adipocytes to identify compounds for metabolic activity regulation. The patent is expected to issue on December 26, 2023, as U.S. Patent No. 11,851,682. The CEO highlighted the importance of this milestone in developing tools for screening compounds targeting metabolic disorders.
December 12, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioRestorative Therapies has been granted a notice of allowance for a patent related to its obesity program, which is a positive development for the company's intellectual property and product pipeline.
The notice of allowance for a new patent is a significant positive development for BioRestorative Therapies, as it strengthens the company's intellectual property portfolio and supports the development of its ThermoStem program. This could lead to increased investor confidence and potential partnerships or funding opportunities, which may positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100